Optometrists in Villa Grove, IL Accepting Medicare
2 Optometrists found. Showing 1 - 2
 Dr. Steve Alan Leon, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 10 W Adams Ave, Villa Grove, IL 61956 Phone: 217-832-2111 Fax: 217-832-9935 |
 Leon Optometric Clinic Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 10 W Adams Ave # 200, Villa Grove, IL 61956 Phone: 217-832-2111 Fax: 217-832-9935 |
News Archive
Researchers test promising new breast cancer drugs
The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.
Proteomics yields new drug targets for treating cardiogenic shock
When it comes to cell signaling and bioregulation, it's tough to find a more important molecule than nitric oxide (NO). Dysfunction of NO-mediated signaling is thought to be a culprit in lethal cardiovascular conditions such as angina, and septic, cardiogenic and hemorrhagic shock; it may play a role in many other illnesses as well.
Botox - a potential for therapy of weak bladders in women
The study, published in the journal European Urology, was carried out at eight uro-gynecology centers in the UK from 2006 to 2009 by researchers from the University of Leicester. A total of 240 women were split into two groups, with 122 women given Botox and 118 receiving a dummy treatment. Researchers found improvements across a range of symptoms, including wetting oneself and feeling a need to rush to the toilet, and how often the women 'leaked' urine.
Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
Results from Abbott's multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012
Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.
› Verified 8 days ago